MedTrace Logo

A Phase Ⅱ Study of Mosapride Citrate Injection in the Treatment of Postoperative Gastrointestinal Dysfunction

NCT06782594 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2025-01-20

No results posted yet for this study

Summary

This study is a multicenter, randomized, double-blind, parallel, placebo-controlled phase II clinical study.

Conditions

  • Postoperative Gastrointestinal Dysfunction

Interventions

DRUG

Mosapride Citrate Injection(high)

Mosapride Citrate Injection, iv, 8mg, bid, for 3 to 5 days

DRUG

Mosapride Citrate Injection(low)

Mosapride Citrate Injection, iv, 4mg, bid, for 3 to 5 days

DRUG

Placebo

Placebo, iv, bid, for 3 to 5 days

Sponsors & Collaborators

  • Shandong New Time Pharmaceutical Co., LTD

    lead INDUSTRY

Principal Investigators

  • Guihua Wang, MD · TONGJI HOSPITAL AFFILIATED TO TONGJI MEDICAL COLLEGE HUST

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-10-18
Primary Completion
2025-06-30
Completion
2025-10-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06782594 on ClinicalTrials.gov